The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
AIM: Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS). METHODS: One hundred fifty-five patients with PCOS were enrolled in this prospective, open-label clinical study. Patients were assigned to receive oral treatment with OCP alone (estradiol (EE) 30 μg/gestodene 75 μg) or in combination with myo-inositol 4 g/die, for 12 months. RESULTS: OCP plus MI therapy resulted in a higher reduction of FG score compared with OCP alone therapy. The combined therapy (OCP plus MI) significantly decreased hyperinsulinaemia, by positively affecting the fasting insulin and glucose levels and homeostasis model assessment-insulin resistance parameters, while no significant changes were observed in the OCP group. Androgens serum levels decreased in both groups, but significantly more in the combined therapy group. The lipid profile was improved in the combined therapy group, by reducing low-density lipoprotein cholesterol levels and enhancing high-density lipoprotein cholesterol levels. CONCLUSIONS: Our data show that a combination of combined contraceptive pill and MI may be more effective in controlling endocrine, metabolic, and clinical profile in patients with PCOS than OCP alone, and may reduce insulin levels and insulin resistance. Hence, combined treatment may become a more effective long-term therapeutic choice for controlling PCOS symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“A deficiency of myo-inositol has been found in women with PCOS affected by insulin resistance [26], and the administration of myo-inositol reduces serum insulin, decreases serum testosterone, and enhances ovulation [26–28].”
Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus
Ovalle, F., & Azziz, R. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03111-4 · Cited by 428
Nelson, V. L., Qin, K.-N., Rosenfield, R. L., Wood, J. R., Penning, T. M., Legro, R. S., Strauss, J. F., & McAllister, J. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8088 · Cited by 405
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188
Meyer, C., McGrath, B. P., & Teede, H. J. (2007) · Diabetes Care · doi:10.2337/dc06-0618 · Cited by 148
Mastorakos, G., Koliopoulos, C., & Creatsas, G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02993-x · Cited by 137
Berneis, K., Rizzo, M., Lazzaroni, V., Fruzzetti, F., & Carmina, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1705 · Cited by 121 · cited 1×
“This finding is especially important considering that decreased HDL cholesterol levels are among the most common lipid abnormalities associated with PCOS [37,38] and are a recognized cardiovascular risk factor [39].”
Background
Research works printed but not linked: 30
- Asuncion M, 2000, J Clin Endocrinol Metab, 85, 2434
- Diamanti-Kandarakis E, 2006, Endocrinol Nutr, 53, 25, 10.1016/S1575-0922(06)71062-2 · DOI
- Escobar-Morreale HF, 2005, Endocr Rev, 26, 251, 10.1210/er.2004-0004 · DOI · Paper page
- Gambineri A, 2006, Endocrinol Nutr, 53, 49
- Alvarez-Blasco F, 2006, Arch Intern Med, 166, 2081, 10.1001/archinte.166.19.2081 · DOI · Paper page
- Dunaif A, 1997, Endocr Rev, 18, 774
- Utiger RD, 1996, N Engl J Med, 335, 657, 10.1056/NEJM199608293350909 · DOI · Paper page
- Apridonidze T, 2005, J Clin Endocrinol Metab, 90, 1929, 10.1210/jc.2004-1045 · DOI · Paper page
- Cattrall FR, 2004, Best Pract Res Clin Obstet Gynaecol, 18, 803, 10.1016/j.bpobgyn.2004.05.005 · DOI
- Dejager S, 2001, Clin Endocrinol (Oxf), 54, 455, 10.1046/j.1365-2265.2001.01245.x · DOI · Paper page
- Castelo-Branco C, Gynecol Endocrinol, 26, 736, 10.3109/09513590.2010.481025 · DOI · Paper page
- Hardiman P, 2003, Lancet, 361, 1810, 10.1016/S0140-6736(03)13409-5 · DOI · Paper page
- Speroff L, 2005, Clinical gynecologic endocrinology and infertility
- 10.2165/00003495-200464210-00006 · DOI
- Harborne L, 2003, Lancet, 361, 1894, 10.1016/S0140-6736(03)13493-9 · DOI · Paper page
- 10.1097/00003081-200306000-00011 · DOI · Paper page
- Baillargeon JP, 2008, Hum Reprod, 23, 1439, 10.1093/humrep/den097 · DOI · Paper page
- 10.2337/diacare.29.02.06.dc05-1070 · DOI · Paper page
- Nestler JE, 1997, J Clin Endocrinol Metab, 82, 4075
- Minozzi M, 2008, Reprod Biomed Online, 17, 579, 10.1016/S1472-6483(10)60248-9 · DOI
- 10.1080/09513590701672405 · DOI · Paper page
- Costantino D, 2009, Eur Rev Med Pharmacol Sci, 13, 105
- 2004, Fertil Steril, 81, 19
- 10.1210/jc.2002-021528 · DOI · Paper page
- Frempong BA, 2008, J Clin Endocrinol Metab, 93, 2097, 10.1210/jc.2007-2599 · DOI · Paper page
- van Rooijen M, 2002, Am J Obstet Gynecol, 186, 44, 10.1067/mob.2002.119179 · DOI
- Ferriman D, 1961, J Clin Endocrinol Metab, 21, 1440, 10.1210/jcem-21-11-1440 · DOI · Paper page
- 10.1080/09513590903015544 · DOI · Paper page
- Rajkhowa M, 1997, J Clin Endocrinol Metab, 82, 3389
- Tornvall P, 1996, Metabolism, 45, 1375, 10.1016/S0026-0495(96)90118-3 · DOI
Cited by
Pacchiarotti, A., Carlomagno, G., Antonini, G., & Pacchiarotti, A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1101444 · Cited by 111
RetractedBenelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3204083 · Cited by 100
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
Günalan, E., Yaba, A., & Yılmaz, B. (2018) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.2018.0077 · Cited by 74
Shokrpour, M., Foroozanfard, F., Afshar Ebrahimi, F., Vahedpoor, Z., Aghadavod, E., Ghaderi, A., & Asemi, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540570 · Cited by 63
Metadata
- Authors
- Minozzi, M., Costantino, D., Guaraldi, C., & Unfer, V.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2011-03-21
- Volume
- 27
- Issue
- 11
- Pages
- 920-924
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2056107937
- Cited by
- 56
- References
- 9
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. https://app.cochat.ai/papers/10.3109/09513590.2011.564685
- The paper
- Minozzi, M., Costantino, D., Guaraldi, C., & Unfer, V. (2011). The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2011.564685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.